Treatment Pathway
Treatment of Polycythemia Vera
Polycythemia vera is a myeloproliferative neoplasm causing overproduction of red blood cells, increasing blood viscosity and thrombosis risk. Symptoms include headache, itching after bathing, facial redness, and splenomegaly; phlebotomy is a primary treatment.
ESMO (European Society of Medical Oncology)ASCO (American Society of Clinical Oncology)NCCNASH (Hematology)NICE Oncology Guidance
Managing Polycythemia Vera effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Polycythemia Vera can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Multidisciplinary team (MDT) approach: oncology, surgery, radiotherapy, pathology, palliative care
- ✓Stage-appropriate intent: curative vs. palliative — informs treatment intensity and goals
- ✓Systemic therapy: chemotherapy, targeted therapy, immunotherapy (checkpoint inhibitors), hormone therapy
- ✓Surgical resection: primary curative approach for solid tumours when localised
- ✓Radiotherapy: definitive, adjuvant, or palliative depending on tumour type and stage
What to Do Now
- Learn your personal risk factors for Polycythemia Vera (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Polycythemia Vera
- Use our AI symptom checker to assess whether your symptoms fit an early Polycythemia Vera pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Polycythemia Vera-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Nutritional support: maintain weight and muscle mass; dietitian involvement
- •Physiotherapy and exercise oncology: reduced fatigue, improved outcomes
- •Psychological support: validated cancer-specific interventions (CBT, supportive psychotherapy)
- •Smoking cessation and alcohol reduction: reduces treatment toxicity and second primary cancers
- •Palliative care integration from diagnosis: symptom management, advance care planning
- •Fertility preservation: discuss before gonadotoxic therapy in reproductive age patients
- •Sun protection post-treatment: radiation-sensitised skin; immunosuppressed skin cancer risk
Treatment Goals
🎯Cure or long-term remission in localised and haematological malignancies
🎯Disease control: stable or partial response in metastatic/advanced settings
🎯Symptom palliation and quality of life preservation
🎯Overall survival and progression-free survival improvement
🎯Survivorship: management of long-term treatment sequelae
Monitoring Parameters
- ◆Tumour markers: PSA (prostate), CA-125 (ovarian), CEA (colorectal), AFP (liver) — at defined intervals
- ◆Imaging: CT/MRI/PET per tumour-specific response criteria (RECIST)
- ◆FBC: myelosuppression monitoring during chemotherapy — weekly during active treatment
- ◆Cardiotoxicity: LVEF monitoring with anthracyclines and trastuzumab (echo before, during, after)
- ◆Renal and hepatic function: before each chemotherapy cycle; drug dose adjustments
- ◆Peripheral neuropathy grading: platinum and taxane-based regimens
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Polycythemia Vera — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Polycythemia Vera combined with new relevant symptoms
- ⚠Sudden worsening of Polycythemia Vera symptoms despite established treatment
Escalation Criteria
- →Febrile neutropenia: broad-spectrum IV antibiotics within 1 hour of presentation; emergency
- →Progressive disease on first-line treatment → second-line regimen; clinical trial consideration
- →Oncological emergencies: spinal cord compression, SVC syndrome, tumour lysis syndrome → urgent oncology review
- →Deteriorating performance status → reassess treatment goals; palliative focus
Special Populations
Elderly: comprehensive geriatric assessment (CGA) before initiation; adjust for organ function and polypharmacy
Children: paediatric oncology specialist; growth/developmental monitoring; school integration
Pregnancy: individualised risk-benefit; most chemotherapy avoided in 1st trimester; tumour board involvement
Genetic cancer syndromes: BRCA/Lynch testing; cascade testing and family surveillance
Clinical Insights
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →